GeneDx Holdings Corp. is −48% over the past year while the S&P 500 is +18%: 66 points behind the market. Through the fall, its own insiders bought $90M more stock than they sold. 1-year return: −48% (S&P 500 +18%). vs 200-day average: −18%, a clear downtrend. RSI (14): 18, oversold, sold harder than it has been bought. Below its 52-week high: 60%.

WGSGeneDx Holdings Corp.

Healthcare

$67.31-48% 1Y

$67.31

$34.5152 weeks$167.51

What is the market doing?

Watch

The market is leaning against it: in a downtrend (−18% vs 200-day) and a crowded short (+20% of shares).

2 to watch, 1 neutral

TrendDowntrendderived · Oct 9, 2026

In a downtrend, below its 50- and 200-day averages. Oversold (RSI 18). Price is −18% vs its 200-day average.

Insider conviction−$1.8M (90 days to Oct 8, 2026)SEC EDGAR · Oct 8, 2026

Insiders were net sellers over the 90 days ending Oct 8, 2026; selling is often routine (taxes, diversification).

Short interest20% of sharesFINRA · Sep 15, 2026

A crowded short, settled Sep 15, 2026, more than a week of normal trading to cover, a crowded exit.

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

1-year returnbottom 5% of the market

vs 200-day avgbehind 84% of the market

Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.

How WGS is trading

GeneDx Holdings Corp. is −48% over the past year while the S&P 500 is +18%: 66 points behind the market. Through the fall, its own insiders bought $90M more stock than they sold.

−48%

1-year return · S&P 500 +18%

vs 200-day average: −18%
vs 200-day average · a clear downtrend
RSI (14): 18
RSI (14) · oversold, sold harder than it has been bought
Below its 52-week high: 60%
Below its 52-week high

Sep 18, 2024$17.21 – $167.51 · dashed line: 200-day averageOct 9, 2026

Details›

Last close2026-10-09: $67.31
1 monthS&P 500 +2.7%: −20%
1 yearS&P 500 +18%: −48%
5 yearsS&P 500 +88%: −77%
vs 50-day average$81.40: −17%
52-week high: $167.51
52-week low: $34.51
Annualised volatility: 99%
Insider buying, net, 6 monthsForms 3/4/5 to 2026-10-08: $90M

Calendar-year price return
Year	Return
2026 (year to date)	−48%
2025	+69%
2024	+2695%
2023	−68%
2022	−94%
2021	−60%

Average return by calendar month, 2020–2026
Month	Years	Positive	Average
Jan	6	3 of 6	+10%
Feb	6	5 of 6	+35%
Mar	6	1 of 6	−14%
Apr	6	1 of 6	−0.59%
May	6	2 of 6	−4.1%
Jun	6	4 of 6	+7.8%
Jul	6	4 of 6	+9.9%
Aug	6	2 of 6	−5.2%
Sep	6	1 of 6	−8.5%
Oct	6	4 of 6	+15%
Nov	5	1 of 5	−13%
Dec	6	2 of 6	−4.8%

End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.

On our screens:Most shorted stocks

Diagnostics & Research

Ranks #9 of 21 by RyuScore

Adaptive Biotechnologies Corporation

OPK+1.5%

OPKO Health, Inc.